User:Mr. Ibrahem/Dengue vaccine

Dengue vaccine is a vaccine used to prevent dengue fever in humans. , one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected. It is given as three injections over a year.

Common side effects include headache, pain at the site of injection, and general muscle pains. Severe side effects may include anaphylaxis. Use is not recommended in people with poor immune function. Safety of use during pregnancy is unclear. Dengvaxia is a weakened but live vaccine and works by triggering an immune response against four types of dengue virus.

, the dengue vaccine had been approved for medical use in 19 countries, including the United States in 2019. It is on the World Health Organization's List of Essential Medicines. In Indonesia it costs about US$207 for the recommended three doses as of 2016. Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. Several other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.